Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ONCORED

Financiado

Cerrado

An unrivalled medical device based on red light photo biomodulation to prevent...

An unrivalled medical device based on red light photo biomodulation to prevent improve and remove oral mucositis and dermatitis chemo radio induced as a side effect of cancer treatment Today the healthcare system is under great pressure, suffering the challenges brought by cancer and the ageing of the population. Among these challenges is the need for treating oral mucositis (OM) and dermatitis. Both are conside... ver más

30/11/2018

NEOMEDLIGHT

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

NEOMEDLIGHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2018-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

NEOMEDLIGHT

50.00K€ | Lider

MONOCROM

183.04K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

CareMin650 An unrivalled medical device for severe cancer treatment com... 3M€ Cerrado

Murnia Prevention of Radiotherapy and Chemotherapy Induced Oromucos... 75K€ Cerrado

MUCOSITIS PLATFORM Development of a multidisciplinary platform for the screenin... 279K€ Cerrado

PID2019-108970RB-I00 EFICACIA Y SEGURIDAD DE LA TERAPIA FOTODINAMICA EN FISTULA A... 28K€ Cerrado

NEUROGUT Targeted insula stimulations as treatment for autoimmune dis... 150K€ Cerrado

DESARROLLO Y VALIDACIÓN FUNCIONAL DE UN DISPO... DESARROLLO Y VALIDACIÓN FUNCIONAL DE UN DISPOSITIVO MÉDICO P... 382K€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2018-07-20
Fecha Fin: 2018-11-30

Líder del proyecto

NEOMEDLIGHT No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Today the healthcare system is under great pressure, suffering the challenges brought by cancer and the ageing of the population. Among these challenges is the need for treating oral mucositis (OM) and dermatitis. Both are considered as adverse effects of radio and chemo-therapy employed during the treatment of some cancers, specially leukaemia, head & neck cancers and breast cancers which only generate dermatitis. There is an increase incidence of cancers worldwide, for instance, 842,000 new cases of head and neck cancer were diagnosed in 2017. In addition, leukaemia counts with around 352,000 new cases diagnosed in 2015. And breast cancer is the second most common cancer with 1.7 million new cancer cases diagnosed in the year 2015. These inflammations, occur in 100% of patients that are receiving chemotherapy high‐dose. In views of the situation, there is an urgent need to treat these chemo and radio therapy-associated diseases but the current medical devices are ill adapted since the radiation emitted cannot be controlled in a homogenous way, resulting in an inefficient treatment of OM and dermatitis. In response, NEOMEDLIGHT have developed ONCORED, an innovative medical device based on photo biomodulation for the non-harmful treatment of oral mucositis and dermatitis. ONCORED seeks to simplify workflows at the clinical level enabling the prevention, improvement and removal of OM and dermatitis with homogenous red-light whose dose (energy and power) can be well controlled. Having validated the reliability of the ONCORED system at the pilot scale, we now want to finalise its development and achieve market preparedness. In Phase 1 we aim to carry a Feasibility Study to warrant the project from a technical, commercial and financial point of view. Besides the crucial benefits that it will bring to healthcare, ONCORED will boost the growth of NEOMEDLIGHT, expecting to gain € 27 million gross profit and 16 new people after 5 years in the market, reaching a ROI of 5.49.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores